oprozomib + lenalidomide + dexamethasone

This combination therapy consists of **oprozomib**, **lenalidomide**, and **dexamethasone**, all oral agents investigated for the treatment of multiple myeloma, particularly in relapsed/refractory disease. - **Oprozomib** is an oral, irreversible proteasome inhibitor structurally related to carfilzomib, inhibiting the chymotrypsin-like activity of the proteasome, leading to apoptosis in multiple myeloma (MM) cells including those resistant to other therapies. Oprozomib additionally exerts anti-angiogenic and proapoptotic activity, activating caspase cascades and inhibiting migration of MM cells[2]. - **Lenalidomide** is an immunomodulatory agent (IMiD), derivative of thalidomide, which directly induces growth arrest and apoptosis, inhibits MM cell adhesion to the bone marrow stromal cells and extracellular matrix, modulates cytokine secretion, inhibits angiogenesis, and augments anti-tumor immunity[4]. - **Dexamethasone** is a synthetic corticosteroid that induces apoptosis of MM cells, inhibits expression of interleukin-6 (IL-6) through inhibition of NF-κB and other transcription factors, thus reducing proliferation and survival of MM plasma cells[6]. Investigational and early clinical studies suggest this combination has clinical activity and tolerability in relapsed/refractory multiple myeloma, with enhanced anti-myeloma effects mediated by the different mechanisms of each component[2][4][6].

Other names

oprozomib + lenalidomide + dexamethasone